Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study

British Medical Journal

Volumn 312, Issue 7023, 1996, Pages 83-88

  Spitzer, Walter O ^a,e   Lewis, Michael A ^a   Heinemann, Lothar A J ^b   Thorogood, Margaret ^c   MacRae, Kenneth D ^d  

^a MCGILL UNIVERSITY   (Canada)

^b Berlin Center for Epidemiology and Health Research   (Germany)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^e Potsdam Inst P/TA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; UNITED KINGDOM; VEIN THROMBOSIS;

EID: 0029671042     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.312.7023.83     Document Type: Article

References (12)

1. Vessey MP. Benefits and risks of combined oral contraceptives. Methods Inf Med 1993;32:222-4.
2. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981;305:612-8, 672-7.
3. Goldzieher JW. Advances in oral contraception. An international renew of levonorgestrel and ethinyl estradiol. J Reprod Med 1983; 23(suppl 1):53-6.
4. Thorogood M. Oral contraceptives and cardiovascular disease: an epidemiologic overview. Pharmacoepidemiol Drug Saf 1993;2:3-16.
5. Kuhl H, Jung-Hoffman C, Heidt F. Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestiadiol and 75 micrograms gestodene. Contraception 1988;38: 477-86.
6. Jung-Hoffman C, Kuhl H. Interaction with the pharmacokinctics of ethinylestradiol and progestogens contained in OCs. Contraception 1989;40: 299-312.
7. Poulter N, et al. A multinational case-contral study of cardiovascular disease and steroid hormone contraceptives. J Clin Epidemiol (in press).
8. Spitzer WO, Thorogood M, Heinemann L. Trinational case control study of OCs and health. Pharmacoepidemiol Drug Saf 1993;2:21-31.
9. Lewis MA, Assmann A, Heinemann L, Spitzer WO. Transnational case-control study of oral contraceptives and health. Approved protocol revisions through September 1995. Pharmacoepidemiol Drug Saf (in press).
10. Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol 1974;99:325-32.
11. Cole P, MacMahon B. Attributable risk percent in case-control studies. Br J Prev Soc Med 19971;25:212-4.
12. Levin ML. The occurrence of lung cancer in man. Acta Unio Int Cancer 1953;9:531-41.